Next-Generation Tumour Models for Triple Negative Breast Cancer: Development of Vascularized 3D Models Using Patient-Derived Cells
- Asees Kaur
- Jul 29
- 2 min read
Updated: Aug 1
Victoria, July 2025—VoxCell BioInnovation is excited to announce a strategic collaboration with Inaphaea BioLabs, a wholly owned subsidiary of ValiRx Plc, focused on developing advanced, vascularized 3D in vitro tumour models incorporating Inaphaea’s clinically relevant Patient Derived Cells (PDCs).
The collaboration will initially focus on Triple Negative Breast Cancer (TNBC), a highly complex and aggressive cancer subtype with limited therapeutic options. Together, VoxCell and Inaphaea will co-develop fully perfusable, vascularized 3D tumour models that integrate patient-derived cells, offering researchers a more predictive platform for evaluating drug efficacy, safety and toxicity.
The joint teams will apply these models to evaluate the nano-formulated delivery of ValiRx’s Clx001, an oncolytic peptide therapy. This includes testing for tumour penetration, targeting, and accumulation, all within a physiologically relevant microenvironment.
By combining their PDC models with our vascularized 3D bioprinting technology, we will create more predictive, human-like tumour tissues for drug screening. This collaboration not only aims to generate valuable efficacy and tumour penetration data for Clx001, but also sets the foundation for expanding our partnership to other cancer indications.
Dr. Karolina Valente, CEO of VoxCell BioInnovation
Supporting the Shift Toward New Approach Methodologies
This collaboration supports the growing industry and regulatory push toward New Approach Methodologies (NAMs) - innovative, non-animal-based tools that more accurately reflect human biology. As the FDA continues to move away from animal testing, human-relevant platforms like 3D vascularized models using patient-derived cells are becoming essential. These next-generation models elevate ethical standards in research, enhance translational relevance, and align with the FDA’s roadmap for improving drug development through more predictive, human-based systems.
About VoxCell BioInnovation
VoxCell BioInnovation is a leading provider of next-generation in vitro models, powered by our 3D bioprinted, vascularized tissue technology. Our ready-to-perfuse models closely replicate human biology with in vivo–like microvascular networks, enabling nutrient and oxygen delivery, systemic drug distribution, and more predictive therapeutic responses. VoxCell’s end-to-end solution offers researchers and pharmaceutical companies a scalable, ethical alternative to animal testing. Our mission is to reduce reliance on animal models, accelerate preclinical development, and advance more effective therapies for patients.
Want to learn more or collaborate?
Visit our website, connect with us on LinkedIn, or email us at hello@voxcellbio.com.
